If you bought NEU near its peak, watching the chart slide lower does not give you a good feeling. A company with its first approved drug for a rare paediatric disorder, rapidly growing royalty income and a deep pipeline sounds like the kind of story the market should love. Yet over the last couple of years, the Neuren Pharmaceuticals share price has swung widely, rallying hard and then falling back to test investors’ nerves again and again. Today, the big question many holders are asking is simple but uncomfortable: has NEU already put in its low, or could there be another painful leg down?

Who is Neuren Pharmaceuticals (ASX: NEU)?

Neuren Pharmaceuticals is an Australian biopharmaceutical company focused on treatments for severe neurodevelopmental disorders that appear in early childhood. These conditions, such as Rett syndrome and Angelman syndrome, are rare. Still, they are often devastating for patients and families, and until recently, had no disease-specific therapies at all. Neuren’s strategy has been to specialise in this niche, building scientific expertise and a focused portfolio rather than competing across the entire neurology space.

The company’s lead success so far is trofinetide, marketed in the United States as DAYBUE, the first approved treatment for Rett syndrome in adults and children aged two and over. DAYBUE received US marketing approval in March 2023, a major de-risking event for Neuren’s business model and a key driver of the earlier surge in Neuren Pharmaceuticals' share price.

A partnering-driven business model

Neuren does not commercialise DAYBUE itself in the US. Instead, it has granted a worldwide licence to Acadia Pharmaceuticals, a US biopharma company with an established commercial infrastructure. Under this deal, Acadia funds the late-stage development and commercialisation of DAYBU and E, while Neuren receives a mix of milestone payments and royalties on net sales.

This model is important when thinking about the Neuren Pharmaceuticals share price. Neuren avoids the heavy capital costs of building a salesforce, but it is also heavily exposed to its partners' commercial execution. If DAYBUE uptake is slower or faster than the market expects, NEU’s valuation will respond accordingly, even though Neuren itself isn’t doing the selling.

Pipeline beyond DAYBUE

Neuren’s second main asset is NNZ-2591, a small-molecule candidate being studied across several rare genetic neurodevelopmental syndromes, including Phelan-McDermid, Angelman, Pitt-Hopkins and Prader-Willi syndromes. Phase 2 trials have produced encouraging signals across multiple syndromes, suggesting that NNZ-2591 may target core symptoms common to several disorders rather than a single mutation.

From a valuation perspective, this matters because Neuren is increasingly seen not just as a “one-drug royalty story” but as a platform for multiple ultra-rare indications. In bull phases for biotech stock,s that kind of pipeline optionality can lead to optimistic pricing. In a more cautious market, ts it can flip the other way, with investors demanding a large discount to reflect execution and regulatory risk. That tug-of-war is evident in the volatility of Neuren Pharmaceuticals' share price over the last few years.

What Investors Should Know About NEU’s Recent Lows

To understand whether the Neuren Pharmaceuticals share price has bottomed, you first need to know how it got here. Over the last couple of years, NEU has delivered both spectacular gains and gut-wrenching declines.

In 2025, the stock traded between roughly A$8.6 at the low and just under A$23 at the high, finishing the year substantially above where it started. In 2026 so far (to late February), the range has been lower, around A$12 to A$21, with the last price visible in many feeds around A$13–14 per share. That means current levels sit much closer to the lower end of the recent range than the top.

From a longer-term perspective, the Neuren Pharmaceuticals share price still reflects enormous value creation versus the pre-approval days. But for anyone who bought near the post-DAYBUE euphoria, the recent pullback feels painful. Several factors appear to have contributed to NEU’s slide toward recent lows.

1. Normalisation after a big re-rating

The first big leg up in NEU coincided with the run-up to and approval of DAYBUE for Rett syndrome by the U.S. Food and Drug Administration (FDA) in March 2023. Approval removed a huge binary risk and opened the door to royalty revenue. It is common in biotech for the share price to run ahead of fundamentals around this type of catalyst, then consolidate as real-world sales data trickles in, and analysts refine their models.

Neuren has reported rapid growth in DAYBUE sales and royalty income. For instance, information released in Q1 2024 pointed to quarterly net sales of roughly US$76 million and a sharp increase in Neuren’s royalty take compared with the prior year. However, the market had high expectations, and as those expectations were tested against guidance and actuals, the gap between hope and reality likely narrowed, contributing to volatility in the Neuren Pharmaceuticals share price.

2. Renewed competition for investor attention

In 2023 and early 2024, stories about rare diseases and neuroscience were hot globally. By 2025–2026, investor attention had broadened back out to areas like weight-loss drugs, oncology platforms, and, of course, large-cap tech and AI names. When risk appetite shifts, mid-cap healthcare often sees outflows even when fundamentals remain strong. That “style drift” may help explain why NEU has pulled back even during periods when its operating updates have been broadly positive.

3. Macro and interest-rate headwinds

Biotech is inherently long-duration: much of the value lies in cash flows far in the future. When interest rates are high or rising, those future cash flows are discounted more heavily, which tends to compress multiples on growth stocks. The global rate environment over the last couple of years has therefore been a headwind to richly valued healthcare names, and the Neuren Pharmaceuticals share price has not been immune.

4. Event risk around NNZ-2591

Neuren’s second asset, NNZ-2591, is moving toward larger late-stage studies. Each positive Phase 2 readout has helped support the story, but as the company moves closer to pivotal data, investors price in binary risk on both the upside and the downside. Any hint of delay, change in study design, or cautionary language can make the market skittish, feeding into bouts of weakness in the Neuren Pharmaceuticals share price.

5. Technical factors and profit-taking

Many shareholders are sitting on large gains from earlier years. When a stock that has run hard starts to slide, some long-term holders decide to “bank profits” rather than sit through another round trip. That selling can push the price below clear chart levels, triggering stop losses for shorter-term traders. You then get a cascade of technical selling that has more to do with portfolio mechanics than with Neuren’s underlying business.

Can Neuren’s Share Price Recover from Recent Declines?

Source: Neuren Pharmaceuticals

Now we come to the heart of the question: from current levels, is NEU closer to the bottom or the top of its likely range over the medium term? No one can know for sure, but you can map the factors that would typically support a recovery in the Neuren Pharmaceuticals share price, as well as those that might push it lower.

Fundamental drivers that could support a recovery

In the medium term, share prices tend to follow fundamentals more than sentiment. For Neuren, several fundamental levers stand out:

● DAYBUE sales trajectory: If Acadia continues to grow DAYBUE sales in Rett syndrome and can maintain or expand pricing, Neuren’s royalty income should rise accordingly. Stronger-than-expected adoption across US treatment centres could justify a higher valuation multiple and support a rerating of the Neuren Pharmaceuticals share price.

● Label and geographic expansion: There is potential for DAYBUE (or its new powder formulation, DAYBUE STIX) to gain approvals in other regions and for other formulations to make treatment easier for families. The recent FDA approval of DAYBUE STIX, a dye- and preservative-free powder version, widens options for patients and caregivers and reinforces the franchise.

● Progress of NNZ-2591: Successful Phase 3 design, regulatory engagement and eventual pivotal data could crystallise value across multiple rare indications. Each positive milestone reduces uncertainty and can underpin higher long-term revenue assumptions in analyst models.

● Balance sheet strength: Royalty inflows and past capital raisings have put Neuren in a more comfortable cash position than many small biotechs. The less investors worry about another large equity raising at depressed prices, the easier it is for the Neuren Pharmaceuticals share price to recover when sentiment turns.

If these building blocks fall into place, NEU does not need perfect conditions to trade above recent lows. In particular, clarity on DAYBUE’s peak sales potential and visible progress on NNZ-2591 could gradually shift the narrative from a “post-approval hangover” to a “multi-asset rare disease growth story”.

Sentiment, charts and what a bottom might look like

Even in fundamentally driven markets, technicals and sentiment matter. Without trying to predict specific price levels, investors often look for a few common signs that a stock may be forming a bottom:

● Stabilisation in the trading range: Instead of making new lows, the price oscillates in a relatively tight band for some time as sellers are gradually absorbed.

● Volume is drying up on down days: Sharp sell-offs become less violent and are not accompanied by big spikes in volume, suggesting that “forced sellers” are mostly gone.

● Positive news is gaining more traction: Announcements that would previously have been shrugged off are now generating modest, sustained upward moves rather than being sold into.

If you are tracking the Neuren Pharmaceuticals share price day to day, watching for these kinds of behavioural shifts can be just as instructive as poring over valuation spreadsheets. However, they are not guarantees. Stocks can form what appears to be a solid base and then plunge to fresh lows on a single negative headline.

Important Disclaimer: You’re reading a free article that offers general opinions and insights. For exclusive, in-depth research, timely high-conviction investment ideas, and actionable trade signals designed to help you stay ahead, join Proactive Equities today by opening a Free Trial Account now! (No Credit Card Required)

Risks that could undermine a recovery

Balanced analysis also means being clear about risks. For NEU, some of the more obvious downside catalysts include:

● DAYBUE sales falling short of expectations: If payer pushback, competition, side-effect concerns, or practical adherence issues limit real-world uptake, royalty projections might need to be revised downward. That would likely pressure the Neuren Pharmaceuticals share price, even if the absolute level of royalties continues to grow year-on-year.

● Regulatory or safety surprises: Any new safety signal, label restriction, or unexpected regulatory challenge around DAYBUE or NNZ-2591 could hit sentiment hard. In rare paediatric disorders, regulators are sometimes especially cautious.

● Clinical trial disappointments: Failure of a key NNZ-2591 study to meet its endpoints, or even a delay that creates uncertainty, could trigger a sharp repricing of Neuren’s pipeline value. For investors who currently ascribe substantial optionality to NNZ-2591 clinical trial results, that is a central risk to monitor.

● Broader biotech sell-off: If global markets rotate sharply out of growth or risk assets, even companies with solid fundamentals can see their share prices dragged down. NEU is unlikely to be immune if there is another widespread de-risking in healthcare.

Technical analysis of Neuren Pharmaceuticals (ASX: NEU)

Neuren Pharmaceuticals (ASX: NEU) share price forecast

Source: TradingView

Neuren Pharmaceuticals (ASX: NEU) is clearly in a short-term downtrend. The price has fallen from above A$21 in January to around A$13.05, making a series of lower highs and lower lows. This confirms bearish momentum.

The sharp sell-off in early February, supported by high volume, shows strong selling pressure. Since then, the stock has been consolidating between roughly A$12.50 and A$13.80. Volume has decreased during this sideways move, suggesting that panic selling has slowed.

Immediate support sits around A$12.50. If this level breaks, the next downside target could be near A$11.50, where consolidation occurred previously. On the upside, the first resistance is around A$13.80 to A$14.00. A daily close above A$14.00 could open the way toward A$15.50, and possibly A$17.00 if momentum improves.

For short-term traders, a potential strategy could be to buy near A$12.50–A$13.00, with a stop-loss below A$12.30 to limit risk. For breakout traders, a stop-loss just below A$13.20 after a confirmed move above A$14.00 may be more suitable. The trend is still bearish, but a base may be forming. Confirmation requires a higher high above A$14.00 with strong volume.

Final thoughts

Has the Neuren Pharmaceuticals share price definitely bottomed out? The answer is that there is no way to be certain. What we can say is that recent lows reflect a mix of profit-taking after a huge re-rating, shifting risk appetite, macro headwinds and the normalisation that often follows a major drug approval. At the current levels, the stock trades much closer to the bottom than the top of its recent range. Yet, Neuren’ss business has arguably never been stronger, with its first commercial product and a maturing pipeline.

For investors willing to do the work, building a view on NEU means going beyond the daily chart and digging into Rett syndrome treatment demand, DAYBUE market penetration, Neuren’s long-term growth strategy and the risk profile around NNZ-2591. If you want to explore those topics in more depth, it can be helpful to read specialised analyses of ASX biotech valuation methods or disease-area deep dives into rare paediatric neurological disorders, so that you are not simply reacting to headlines.

Whether you believe the Neuren Pharmaceuticals share price has bottomed is less important than whether you understand what you are betting on and what could prove you wrong.

FAQs about Neuren Pharmaceuticals (ASX: NEU)

1. Why has the Neuren Pharmaceuticals share price fallen from its highs?

After DAYBUE’s US approval, NEU enjoyed a big re-rating as investors priced in strong future royalties. Since then, enthusiasm has cooled as expectations have been tested against real-world sales, global risk appetite has shifted, and investors have digested the risks around Neuren’s broader pipeline. Profit-taking by early holders has amplified the pullback.

2. Is Neuren still growing its revenue despite the share price decline?

DAYBUE sales and associated royalties rose significantly through 2024, with Neuren reporting a large year-on-year increase in royalty income, from a positive business perspective, even if the Neuren Pharmaceuticals share price has not moved in a straight line with revenue.

3. What role does DAYBUE STIX play in Neuren’s valuation?

DAYBUE STIX, the new powder formulation of trofinetide, offers patients and caregivers another administration option and may improve adherence in real-world settings. It reinforces DAYBUE as a long-term Rett syndrome franchise, which is supportive for valuation if uptake is strong, but the exact impact will depend on prescribing patterns and pricing.